|
US2008286239A1
|
|
Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
|
|
US2008166373A1
|
|
METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-alpha NUCLEIC ACIDS
|
|
AU2007242949A1
|
|
Methods and compositions for delivery and expression of interferon-alpha nucleic acids
|
|
US2008089890A1
|
|
Methods of polypeptide production
|
|
CA2663854A1
|
|
Methods and compositions for gene therapy
|
|
CA2633087A1
|
|
Adenoviral expression vectors
|
|
MX2007007145A
|
|
Cell lines for production of replication-defective adenovirus.
|
|
AU2005299310A1
|
|
Compositions and methods for short interfering nucleic acid inhibition of Nav1.8
|
|
US2006275261A1
|
|
Adenoviral vectors having a protein IX deletion
|
|
JP2005336199A
|
|
Recombinant adenoviral vector and method of use
|
|
SG133594A1
|
|
Methods and compositions for treatment of interferon-resistant tumors
|
|
US2005271623A1
|
|
Reduction of dermal scarring
|
|
US2005112747A1
|
|
Rat secreted embryonic alkaline phosphatase
|
|
MXPA05013983A
|
|
Polymer encapsulation of adenoviruses.
|
|
NZ543970A
|
|
Methods and compositions for interferon therapy
|
|
WO2004108898A2
|
|
Transfection agents
|
|
AU2004245995A1
|
|
Transfection agents
|
|
US2005142112A1
|
|
Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
|
|
US2004087027A1
|
|
Recombinant adenoviral vector and methods of use
|
|
US2004014709A1
|
|
Methods and compositions for interferon therapy
|
